1-15 of 15
Julie Dubois
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment

Chaja Feige Jacobs, Yannick D'Hargues, Sandra Robrecht, Moritz Fürstenau, Kirsten Fischer, Anna Maria Fink, Stephan Stilgenbauer, Christof Schneider, Eugen Tausch, Carsten Utoft Niemann, Caspar da Cunha-Bang, Julie Dubois, Ellen Van Der Spek, Andre Vlot, Yorick Sandberg, Mark-David Levin, Michael Hallek, Barbara F. Eichhorst, Arnon P. Kater, Fleur S. Peters
Journal: Blood
Blood (2024) 144 (Supplement 1): 1846.
https://doi.org/10.1182/blood-2024-209692
Published: 2024
Journal Articles

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Mark-David Levin, Sabina Kersting, Julie Dubois, Bronno van der Holt, Caspar da Cunha-Bang, Doreen te Raa, Cecile Idink, Fransien De Boer, Jolanda Droogendijk, Koen de Heer, Leonie van der Burg, Marten R. Nijziel, Lidwine Tick, Henriettte Levenga, Matthijs Silbermann, Inge Ludwig, Aart Beeker, Mar Bellido, Anne-Marie Van Der Kevie-Kersemaekers, Clemens Mellink, Ine Meulendijks, Sjoerd Zoun-van den Dool, Martine Abrahamse-Testroote, Gerben Zwezerijnen, Carsten Utoft Niemann, Arnon P. Kater
Journal: Blood
Blood (2024) 144 (Supplement 1): 1013.
https://doi.org/10.1182/blood-2024-207452
Published: 2024
Journal Articles

Mutations in BCOR , CCND2 , NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia

Christian Brieghel, Julie Dubois, Ida Kappel Buhl, Kazem Nasserinejad, Dennis De Rooij, Karl Nyrén, Hoa T Tran, Sabina Kersting, Mattias Mattsson, Juha Ranti, Rogier Mous, Gerrit Jan Veldhuis, Caspar da Cunha-Bang, Mark-David Levin, Valtteri Wirta, Richard Rosenquist, Arnon P. Kater, Carsten Utoft Niemann
Journal: Blood
Blood (2024) 144 (Supplement 1): 586.
https://doi.org/10.1182/blood-2024-204532
Published: 2024
Journal Articles

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Clinical Trials & Observations
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Nadine Kutsch, Florian Simon, Valentin Goede, Manuela Hoechstetter, Carsten Utoft Niemann, Caspar da Cunha-Bang, Arnon Kater, Julie Dubois, Michael Gregor, Philipp Bernhard Staber, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael Hallek
Journal: Blood
Blood (2024) 143 (25): 2588–2598.
https://doi.org/10.1182/blood.2023022564
Published: 2024
Includes: Supplemental data
Journal Articles

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Clinical Trials & Observations
Lina van der Straten, Claudia A. M. Stege, Sabina Kersting, Kazem Nasserinejad, Julie Dubois, Johan A. Dobber, Clemens H. M. Mellink, Anne-Marie F. van der Kevie-Kersemaekers, Ludo M. Evers, Fransien de Boer, Harry R. Koene, John Schreurs, Marjolein van der Klift, Gerjo A. Velders, Ellen van der Spek, Hanneke M. van der Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F. M. Posthuma, Hein P. J. Visser, Ilse Houtenbos, Cecile A. M. Idink, Djamila E. Issa, Ellen C. Dompeling, Henk C. T. van Zaanen, J. Hendrik Veelken, Henriette Levenga, Lidwine W. Tick, Wim E. Terpstra, Sanne H. Tonino, Peter E. Westerweel, Anton W. Langerak, Arnon P. Kater, Mark-David Levin
Journal: Blood
Blood (2023) 142 (13): 1131–1142.
https://doi.org/10.1182/blood.2023020195
Published: 2023
Includes: Supplemental data
Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Clinical Trials & Observations
Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater
Journal: Blood
Blood (2023) 142 (5): 446–459.
https://doi.org/10.1182/blood.2023019634
Published: 2023
Includes: Supplemental data
Journal Articles

Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD - Primary Analysis from the Randomized Phase II Vision HO141 Trial

Carsten Utoft Niemann, Julie Dubois, Christian Brieghel, Sabina Kersting, Lisbeth Enggaard, Gerrit J Veldhuis, Rogier Mous, Clemens Mellink, Johan A Dobber, Christian Bjørn Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Kazem Nasserinejad, Hoa Thi Tuyet Tran, Mark-David Levin, Arnon P. Kater
Journal: Blood
Blood (2021) 138 (Supplement 1): 69.
https://doi.org/10.1182/blood-2021-148630
Published: 2021
Journal Articles

Ibrutinib Treatment in CLL Interrupts CD40 Signaling Capacity and Sensitizes CLL Cells to Venetoclax

Karoline Kielbassa, Marco Haselager, Danique Bax, Julie Dubois, Mark-David Levin, Peter E. Westerweel, Rebecka Svanberg, Carsten Utoft Niemann, Arnon P. Kater, Eric Eldering
Journal: Blood
Blood (2021) 138 (Supplement 1): 1545.
https://doi.org/10.1182/blood-2021-152222
Published: 2021
Journal Articles

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

John F. Seymour, Jenny Qun Wu, Relja Popovic, Barbara Eichhorst, Peter Hillmen, Thomas J. Kipps, Anton W. Langerak, Carolyn Owen, Julie Dubois, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Fengjiao Dunbar, Yanwen Jiang, Brenda Chyla, Michelle Boyer, Maria Thadani-Mulero, Marcus Lefebure, Rosemary Harrup, Arnon P. Kater
Journal: Blood
Blood (2021) 138 (Supplement 1): 1548.
https://doi.org/10.1182/blood-2021-147731
Published: 2021
Journal Articles

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Carsten U. Niemann, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J. Veldhuis, Rogier Mous, Clemens H. M. Mellink, Johan A. Dobber, Christian B. Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa T. T. Tran, Kazem Nasserinejad, Arnon P. Kater
Journal: Blood
Blood (2021) 137 (8): 1117–1120.
https://doi.org/10.1182/blood.2020008608
Published: 2021
Includes: Supplemental data
Journal Articles

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

Marco V. Haselager, Karoline Kielbassa, Johanna ter Burg, Danique J. C. Bax, Stacey M. Fernandes, Jannie Borst, Constantine Tam, Francesco Forconi, Giorgia Chiodin, Jennifer R. Brown, Julie Dubois, Arnon P. Kater, Eric Eldering
Journal: Blood
Blood (2020) 136 (25): 2918–2926.
https://doi.org/10.1182/blood.2019004326
Published: 2020
Includes: Supplemental data
Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Arnon P Kater, MD PhD, Jenny Qun Wu, MS, Julie Dubois, Christopher R Bolen, PhD, Zoe J Assaf, PhD, Peter Hillmen, MD PhD, Barbara F. Eichhorst, MD, Eric F Eldering, PhD, Thomas J. Kipps, MD PhD, Anton W Langerak, PhD, Clemens Mellink, PhD, Anne-Marie Van Der Kevie-Kersemaekers, PhD, Carolyn Owen, MD, Brenda J Chyla, PhD, Elizabeth A Punnoose, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Yanwen Jiang, PhD, John F. Seymour, MBBS, PhD FRACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 356.
https://doi.org/10.1182/blood-2019-123678
Published: 2019
Journal Articles

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Carsten Utoft Niemann, MD PhD, Julie Dubois, Sabina Kersting, MD PhD, Lisbeth Enggaard, MD, Gerrit J Veldhuis, Rogier Mous, MD PhD, Clemens Mellink, PhD, Johan A Dobber, Christian Bjørn Poulsen, MD, Henrik Frederiksen, MD Prof, Ann Janssens, Ida Schjødt, MD PhD, Ellen C Dompeling, Juha Ranti, Mattias Mattsson, MD, Mar Bellido, Hoa T Tran, Kazem Nasserinejad, Mark-David Levin, MD PhD, Arnon P. Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4292.
https://doi.org/10.1182/blood-2019-124377
Published: 2019
Journal Articles

First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment

Iris de Weerdt, MD, Tom Hofland, MSc, Johan Dobber, Julie Dubois, Eric Eldering, PhD, Mehrdad Mobasher, MD MPH, Fransien Croon-de Boer, Mels Hoogendoorn, MD PhD, Gerjo A. Velders, PhD MD, Marjolein van der Klift, Mark-David Levin, MD PhD, Sabina Kersting, MDPhD, Sanne Tonino, MD PhD, Arnon P. Kater, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1860.
https://doi.org/10.1182/blood-2018-99-116283
Published: 2018
Journal Articles

Identification Of MGMT Polymorphisms As Genetic Markers Of Individual Susceptibility To Therapy-Related Myeloid Neoplasms

Julie Dubois, Gabriel Etienne, Audrey Laroche-Clary, Axelle Lascaux, MD, Audrey Bidet, Eric Lippert, Sofiane Aitouferoukh, Veronique Saada, Jean-Baptiste Micol, Krimo Bouabdallah, MD, Jacques Robert
Journal: Blood
Blood (2013) 122 (21): 1545.
https://doi.org/10.1182/blood.V122.21.1545.1545
Published: 2013